Efficacy Analysis of Trastuzumab Combined With FLOT as Neoadjuvant Treatment of Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric Cancer

Abstract

This research aims to assess the efficacy of neoadjuvant trastuzumab with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel for the treatment of human epidermal growth factor receptor 2 positive metastatic gastric cancer. To conduct the research, we recruited 80 patients having human epidermal growth factor receptor 2 positive advanced gastric cancers between January 2020 and December 2021 admitted to our institution and randomly allocated them to the control and observation groups, each with 40 cases. Patients in the 5-fluorouracil, leucovorin, oxaliplatin and docetaxel group served as controls, while those in the observation group underwent a combination of trastuzumab and 5-fluorouracil, leucovorin, oxaliplatin and docetaxel. The short-term curative outcome of patients after neoadjuvant therapy was evaluated; the levels of carcinoembryonic antigen, serum glycoprotein 19-9 and glycoprotein (carcinoembryonic antigen 72-4) were measured by chemiluminescence immunoassay. Side effects experienced by patients in both groups were recorded when they occurred during therapy. The disease control rate and objective response rate of the observation group were found to be statistically and clinically higher than those of the control group (p<0.05), per the findings of the short-term effectiveness assessment. After treatment, there was a notable reduction in serum carcinoembryonic antigen, carcinoembryonic antigen 19-9 and carcinoembryonic antigen 72-4 in both groups (both p<0.05) and the levels of carcinoembryonic antigen 72-4, carcinoembryonic antigen 19-9 and carcinoembryonic antigen in the observation group were considerably lower than the control group (p<0.05). There was no evident difference between the two patient groups in adverse reactions. Trastuzumab combined with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel has high efficacy and safety in neoadjuvant therapy for human epidermal growth factor receptor 2-positive advanced gastric cancer patients and it can be popularized and applied as a new model of clinical treatment.